SAN
JOSE, Calif. and CLEVELAND, May 27, 2022
/PRNewswire/ -- KDx Diagnostics and UroGPO announced today the
partnership to provide the URO17® test (Research Use Only in the
US) for the detection of bladder cancer. URO17® is a non-invasive
urine test with high sensitivity and negative predicted value (NPV)
that can be used to determine the status of active bladder cancer
and to improve patient diagnosis. This is also likely to improve
the treatment path as URO17® is also now available as a Laboratory
Developed Test (LDT) in the United
States. UroGPO will offer reagents and information for the
URO17® test to the members of their Group Purchasing
Organization.
KDx Diagnostics Inc. and UroGPO Announce a
Partnership to Offer the URO17® NON-INVASIVE Urine Test for Bladder
Cancer
With over 85,000 new cases of bladder cancer in the United States every year the most common
symptom of bladder cancer is hematuria, or blood in the urine, and
patients with hematuria need to be subjected to invasive
cystoscopic procedures even though a large majority of patients
with micro-hematuria will not have bladder cancer. The URO17® test,
and its high sensitivity and NPV for bladder cancer, will assist in
ruling these patients out for unnecessary cystoscopy and its
invasive procedure and in turn reduce the work-up.
"We are very excited to partner with UroGPO, the premier urology
network and group purchasing organization in the US, to make our
URO17® test and information available to their network of clinical
laboratories. Through UroGPO, the urology laboratories will have
direct access to ordering with a special in-network pricing which
will facilitate the availability of URO17® to the urologists," says
Sholeh Jahanfard, President of KDx
Diagnostics Inc.
"UroGPO is happy to present this new partnership to our
membership. The URO17® test adds efficiency and precision to the
care of patients with bladder cancer. KDx has taken steps to remove
barriers of access for both physicians and patients which will
ultimately benefit patient outcomes, improve quality of life, and
even mortality," says Palmer
DePetro, Sr. Director, Contracting at Specialty
Networks.
About KDx Diagnostics Inc.
Founded in 2017, KDx is focused on developing non-invasive cancer
tests to improve early detection and therapy decisions in cancer.
The URO17® bladder cancer test developed by KDx may prove to be the
most sensitive and specific for bladder cancer developed to date.
KDx plans to develop tests based on the same biomarker for other
platforms and sample types and expand its product line into other
cancer diagnostic tests. URO17® is available as LDT in the U.S.
About UroGPO
UroGPO, a Specialty Networks Company, is the first and largest
urology-specific Group Purchasing Organization (GPO) in
the United States, comprised of
more than 700 of the largest, most progressive independent urology
practices in the country. Our membership includes more than 7,500
urology providers, including 4,000 practicing urologists in 3,200
locations spanning 49 states. UroGPO is committed to helping
urology groups remain independent by providing them with
pre-negotiated purchasing contracts, development of new revenue
streams such as In-Office Dispensing of Oral therapeutics, Clinical
Guideline Development, and other resources in all areas of urology.
The goals of UroGPO are to build stronger patient relationships by
improving patient care, make significant positive impacts on
in-practice operational efficiencies and streamline operational
costs.
About Specialty Networks
Specialty Networks brings together the functional expertise of
UroGPO, GastroGPO, PPS Analytics, and SN Research to deliver
innovative and meaningful solutions for independent specialty
providers. Specialty Networks serves a highly specialized member
network of 765+ physician group practices consisting of over 7,700
providers in urology and gastroenterology. Specialty Networks'
mission is to help create clinical, economic, and operational value
for our members leading to a positive patient impact.
Contact:
Public Relations
KDx Diagnostics Inc.
408-628-7715
info@kdxdiagnostics.com
URO17 is a registered trademark of KDx.
View original
content:https://www.prnewswire.com/news-releases/kdx-diagnostics-inc-and-urogpo-announce-a-partnership-to-offer-the-uro17-non-invasive-urine-test-for-bladder-cancer-in-the-united-states-301556977.html
SOURCE KDx Diagnostics Inc.